Assay Development, Compound Screening and Drugs

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Assay Development

Compound Screening

Drugs

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.

Compound Screening

Compound Screening Marketing Assay Development Drugs

Target-directed cancer: protein-ligand interactions

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.

Fragment Screening

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays

Drug Discovery Digest

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

Target-directed cancer: protein-ligand interactions

Stay Connected